Alpha-1 antitrypsin - Kamada

Drug Profile

Alpha-1 antitrypsin - Kamada

Alternative Names: AAT-IH; AAT-IV; alpha-1-proteinase inhibitor; G1-AAT IV; Glassia; Inhaled-AAT; IV AAT; Kamada-API

Latest Information Update: 17 Jan 2017

Price : $50

At a glance

  • Originator Kamada
  • Developer Baxter International; Kamada; Shire
  • Class Acute-phase proteins; Alpha globulins; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Immunomodulators; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Bronchiectasis; Alpha 1-antitrypsin deficiency; Cystic fibrosis; Type 1 diabetes mellitus
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alpha 1-antitrypsin deficiency
  • Phase II/III Graft-versus-host disease; Type 1 diabetes mellitus
  • Phase II Bronchiectasis; Cystic fibrosis; Lung transplant rejection

Most Recent Events

  • 01 Jan 2017 Kamada completes a phase II extension trial for Type-1 diabetes mellitus (In children, In adolescents, In adults) in Israel (NCT01661192)
  • 10 Nov 2016 Kamada extends the manufacturing, supply and distribution agreement with Shire for the fourth time
  • 02 Nov 2016 Kamada and Shire plan a phase II/III trial for Graft-versus-host disease (Adjunctive treatment) in USA (IV, Infusion) (NCT02956122; 9206256)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top